| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8457996 | Pathology - Research and Practice | 2018 | 7 Pages |
Abstract
Our result shows that combination of NVP-BEZ235 and SRT1720 may effectively improve late stage breast cancer cells therapeutics approach. Activation of SIRT1 and STAT3 in resistance breast cancer cells improves the in-vitro therapeutic efficacy of CRT.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Daryoush Fatehi, Amin Soltani, Mahdi Ghatrehsamani,